Clinical Trial With Catheter Locking TauroSept® (Taurolidine 2%) or Saline Solution 0,9%

Inclusion Criteria: * Benign underlying disease leading to long-term intestinal failure who will receive HPN and/or fluids (saline and/or glucose) at least 2 times /week over a subcutaneously tunnelled single-lumen Central Venous Catheter (CVC) (Hickman/Broviac or subcutaneous port) for at least one year 1. Patient receives a new single lumen central vascular access device for HPN (new patient starting HPN or patient already on HPN) allocation to Group I = new catheter group\] or 2. Patient is already on HPN for ≥1 year prior to trial inclusion and has a CRBSI rate (bacterial and/or yeast infections) of \>0.3/year and a catheter that has been in place for ≥6 months (allocation to Group II = high risk group). (Previous salvage of this catheter by line-lock antibiotics or other therapeutic interventions is not an exclusion criterion as long as this has been performed at least two months before enrolment in the trial) * Estimated life expectancy ≥1 year * Male or female patient aged 18 - 80 years * Patient is fully able to understand the nature of the proposed intervention and gives written informed consent before entering the trial. Exclusion Criteria: * cannot be expected to comply with the trial plan (substance abuse, mental condition) * has significant cardiovascular disease such as unstable angina, acute myocardial infarction or recent cerebral vascular accident (within 6 weeks); a cardiac rhythm which in the investigators judgment may result in significant hemodynamic effects * has a known hypersensitivity/allergy to taurolidine 2% or saline solution 0.9% and/or their excipients. * is pregnant, lactating, or nursing. * has a current bloodstream infection * has any clinically significant abnormalities in blood coagulation requiring intervention * has received thrombolytic therapy in the 6 weeks prior to insertion (aspirin 80-325 mg daily is acceptable). * has received an investigational drug within 30 days of trial entry * has an antibiotic coated, silver impregnated or antimicrobial cuff catheter * has received a Taurolidine lock previously * has compromised skin integrity, including any infection at the insertion site * has received parenteral or oral antibiotic therapy \<2months prior trial inclusion